Economic Analysis of a New Business for Liposome Manufacturing Using a High-Pressure System

Liposomes as Carriers of Bioactive Compounds in Human Nutrition

This article provides an overview of the literature data on the role of liposomal structures and encapsulated substances in food technology and human nutrition. The paper briefly describes how liposomes are created and how they encapsulate food ingredients, which can either be individual compounds or plant extracts. Another very interesting application of liposomes is their use as antimicrobial carriers to protect food products from spoilage during storage. The encapsulation of food ingredients in liposomes can increase their bioavailability, which is particularly important for compounds with health-promoting properties but low bioavailability. Particular attention was paid to compounds such as phytosterols, which lower blood cholesterol levels but have very low absorption in the human body. In addition, consumer expectations and regulations for liposomes in food are discussed. To date, no in vivo human studies have been conducted to indicate which encapsulation methods give the best results for gastrointestinal effects and which food-added substances are most stable during food storage and processing. The paper identifies further lines of research that are needed before liposomes can be introduced into food.

Use of Silica Nanoparticles for Drug Delivery in Cardiovascular Disease

PURPOSE

Cardiovascular disease (CVD) is the leading cause of death worldwide. The current CVD therapeutic drugs require long-term treatment with high doses, which increases the risk of adverse effects while offering only marginal treatment efficacy. Silica nanoparticles (SNPs) have been proven to be an efficient drug delivery vehicle for numerous diseases, including CVD. This article reviews recent progress and advancement in targeted delivery for drugs and diagnostic and theranostic agents using silica nanoparticles to achieve therapeutic efficacy and improved detection of CVD in clinical and preclinical settings.

METHODS

A search of PubMed, Scopus, and Google Scholar databases from 1990 to 2023 was conducted. Current clinical trials on silica nanoparticles were identified through ClinicalTrials.gov. Search terms include silica nanoparticles, cardiovascular diseases, drug delivery, and therapy.

FINDINGS

Silica nanoparticles exhibit biocompatibility in biological systems, and their shape, size, surface area, and surface functionalization can be customized for the safe transport and protection of drugs in blood circulation. These properties also enable effective drug uptake in specific tissues and controlled drug release after systemic, localized, or oral delivery. A range of silica nanoparticles have been used as nanocarrier for drug delivery to treat conditions such as atherosclerosis, hypertension, ischemia, thrombosis, and myocardial infarction.

IMPLICATIONS

The use of silica nanoparticles for drug delivery and their ongoing development has emerged as a promising strategy to improve the effectiveness of drugs, imaging agents, and theranostics with the potential to revolutionize the treatment of CVD.

Environmental and Sustainability Analysis of a Supercritical Carbon Dioxide-Assisted Process for Pharmaceutical Applications

Drug delivery systems (DDS) are artificial devices employed to enhance drug bioavailability during administration to a human body. Among DDS, liposomes are spherical vesicles made of an aqueous core surrounded by phospholipids. Conventional production methods are characterized by several drawbacks; therefore, Supercritical assisted Liposome formation (SuperLip) has been developed to overcome these problems. Considering that the use of high pressures involves high energy cost, in this paper, sustainability indicators were calculated to quantitatively evaluate the emissions related to the attainment of liposomes containing daunorubicin (a model antibiotic drug) using the SuperLip process. The indicators were depicted using a spider diagram to raise the actual weaknesses of this technique; some variations were proposed in the process layout to solve the critical issues. According to the literature, many studies related to the pharmaceutical industry are expressed in terms of solid, liquid waste, and toxic emissions; however, liposomes have never explicitly been considered for an analysis of environmental sustainability.